Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NEOPRISM-CRC
NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer
- NCT05197322 ↗
- Active, not recruiting
- University College, London
- Deep
We haven't built an HCP commentary report on NEOPRISM-CRC (pembrolizumab in high-risk stage 2 or 3 MMR-deficient colorectal cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NEOPRISM-CRC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 21 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- NEOPRISM-CRC : Neoadjuvant Pembrolizumab Stratified to Tumour Mutation Burden for High Risk Stage 2 or Stage 3 MMR-deficient Colorectal Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Adenocarcinoma of the Colon
- Interventions
- Pembrolizumab; Pembrolizumab
- Arms
- Tumour Mutation Burden high or medium (or MSI-High) · Other
- Tumour Mutation Burden low or unevaluable · Other
- Enrollment
- 88
- Primary outcomes
- Relapse-free survival
- Sponsor
- University College, London with Merck Sharp & Dohme LLC, Sharp, Foundation Medicine, University College London (UCL) Cancer Institute, University of Leeds, University College London Hospitals, Personalis Inc.
- Start
- Jul 20, 2022
- Primary completion
- Nov 1, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05197322 · updated Sep 14, 2026